Chidamide With R-CHOP Regimen for DLBCL Patients
It's a prospective, single arm, open label phase II clinical trial, in which the safety and efficacy of Chidamide plus R-CHOP regimen is accessed in de novo DLBCL patients, who have received 2 courses of R-CHOP but only achieved PR or whose MRD tests for ctDNA revealed positive results.

abbreviation: R-CHOP: the chemo-therapy regimen composed of Rituximab, cyclophosphoamide, etoposide, vincristine and prednisone.

PR: partial remission; MRD:minimal residual disease;
Diffuse Large B Cell Lymphoma
DRUG: Chidamide + R-CHOP regimen
complete remission rate, complete remission rate after treated by Chidamide+ R-CHOP regimen, every 3 months until 30 months after the last patient's enrollment
progression free survival, from date of inclusion to date of progression, relapse, or death from any cause, from the day of treatment to the date of first documented progressionï¼Œup to 30 months after the last patient's enrollment|overall survival, from the date of inclusion to date of death, irrespective of cause, 30 months after the last patient's enrollment|adverse events, any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure, from the date of first cycle of treatment to 30 months after last patient's enrollment
It's a prospective, single arm, open label phase II clinical trial, in which the safety and efficacy of Chidamide plus R-CHOP regimen is accessed in de novo DLBCL patients, who have received 2 courses of R-CHOP but only achieved PR or whose MRD tests for ctDNA revealed positive results.

abbreviation: R-CHOP: the chemo-therapy regimen composed of Rituximab, cyclophosphoamide, etoposide, vincristine and prednisone.

PR: partial remission; MRD:minimal residual disease;